arrow left
arrow right
  • Jeffrey Campise, Christopher R Campise as executor of the estate of Jeffrey James Campise v. Arkema, Inc. f/k/a Pennwalt Corporation for its Caldesene line of products, Aventis Inc. for its Caldesene line of products, Avon Products, Inc., Barretts Minerals Inc., Block Drug Company, Inc. (sued individually and as successor-in-interest to The Gold Bond Sterilizing Powder Company a/k/a The Gold Bond Company) for its Gold Bond line of products, Block Drug Corporation (sued individually and as successor-in-interest to The Gold Bond Sterilizing Powder Company a/k/a The Gold Bond Company) for its Gold Bond line of products, Brenntag North America, Inc. (sued individually and as successor-in-interest to Mineral Pigment Solutions, Inc. and as successor-in-interest to Whittaker Clark & Daniels, Inc.), Brenntag Specialties Llc f/k/a Brenntag Specialties, Inc. f/k/a Mineral Pigment Solutions, Inc. (sued individually and as successor-in-interest to Whittaker Clark & Daniels, Inc.), Bristol-Myers Squibb Company (sued individually and as successor-in-interest to Charles of the Ritz) for its Jean Nate line of products), Chanel, Inc., Charles B. Chrystal Company, Inc., Chattem, Inc. a subsidiary of Sanofi-Aventis U.S. LLC (sued individually and as successor-in-interest to Block Drug Corporation, successor-in-interest to The Gold Bond Sterilizing Powder Company a/k/a The Gold Bond Company) for its Gold Bond line of products, Glaxosmithkline Llc (Sued Individually And As Successor-In-Interest To Block Drug Corporation, Successor-In-Interest To The Gold Bond Sterilizing Powder Company A/K/A The Gold Bond Company For Its Gold Bond Line Of Products And As Successor-In-Interest to Novartis Corporation and Novartis Consumer Health Inc. for its Caldesene line of products), Gsk Consumer Health, Inc. f/k/a Novartis Consumer Health, Inc. f/k/a CIBA Self-Medication, Inc. for its Caldesene line of products, Himmel Management Co. Llc A/K/A Himmel Group formerly d/b/a Martin Himmel, Inc. (sued individually and as successor-in-interest to Block Drug Corporation successor-in-interest to The Gold Bond Sterilizing Powder Company a/k/a The Gold Bond Company) for its Gold Bond line of products, Insight Pharmaceuticals Corporation a subsidiary of Prestige Brands Holdings, Inc. for its Caldesene line of products, Insight Pharmaceuticals Llc, for its Caldesene line of products, Novartis Corporation (sued individually and as a successor-in-interest to CIBA-GEIGY Corporation and its subsidiaries CIBA Consumer Pharmaceuticals and CIBA Self-Medication, Inc.) for its Caldesene line of products, Prestige Brands Holdings, Inc. for its Caldesene line of products, Prestige Consumer Healthcare Inc. f/k/a Prestige Brands, Inc. for its Caldesene line of products, Pti Union, Llc a/k/a Pharma Tech Industries for its Gold Bond line of products, Revlon Consumer Products Corporation (sued individually and as successor-in-interest to Charles of the Ritz) for its Jean Nate line of products, Sanofi-Aventis U.S. Llc (sued individually and as successor-by-merger to Aventis Pharmaceuticals Inc.) for its Caldesene line of products, Sanofi Us Services, Inc. for its Caldesene line of products, Specialty Minerals Inc. (sued individually and as a subsidiary of Minerals Technologies Inc.), Wegmans Food Markets, Inc., Whittaker Clark & Daniels, Inc.Torts - Asbestos document preview
  • Jeffrey Campise, Christopher R Campise as executor of the estate of Jeffrey James Campise v. Arkema, Inc. f/k/a Pennwalt Corporation for its Caldesene line of products, Aventis Inc. for its Caldesene line of products, Avon Products, Inc., Barretts Minerals Inc., Block Drug Company, Inc. (sued individually and as successor-in-interest to The Gold Bond Sterilizing Powder Company a/k/a The Gold Bond Company) for its Gold Bond line of products, Block Drug Corporation (sued individually and as successor-in-interest to The Gold Bond Sterilizing Powder Company a/k/a The Gold Bond Company) for its Gold Bond line of products, Brenntag North America, Inc. (sued individually and as successor-in-interest to Mineral Pigment Solutions, Inc. and as successor-in-interest to Whittaker Clark & Daniels, Inc.), Brenntag Specialties Llc f/k/a Brenntag Specialties, Inc. f/k/a Mineral Pigment Solutions, Inc. (sued individually and as successor-in-interest to Whittaker Clark & Daniels, Inc.), Bristol-Myers Squibb Company (sued individually and as successor-in-interest to Charles of the Ritz) for its Jean Nate line of products), Chanel, Inc., Charles B. Chrystal Company, Inc., Chattem, Inc. a subsidiary of Sanofi-Aventis U.S. LLC (sued individually and as successor-in-interest to Block Drug Corporation, successor-in-interest to The Gold Bond Sterilizing Powder Company a/k/a The Gold Bond Company) for its Gold Bond line of products, Glaxosmithkline Llc (Sued Individually And As Successor-In-Interest To Block Drug Corporation, Successor-In-Interest To The Gold Bond Sterilizing Powder Company A/K/A The Gold Bond Company For Its Gold Bond Line Of Products And As Successor-In-Interest to Novartis Corporation and Novartis Consumer Health Inc. for its Caldesene line of products), Gsk Consumer Health, Inc. f/k/a Novartis Consumer Health, Inc. f/k/a CIBA Self-Medication, Inc. for its Caldesene line of products, Himmel Management Co. Llc A/K/A Himmel Group formerly d/b/a Martin Himmel, Inc. (sued individually and as successor-in-interest to Block Drug Corporation successor-in-interest to The Gold Bond Sterilizing Powder Company a/k/a The Gold Bond Company) for its Gold Bond line of products, Insight Pharmaceuticals Corporation a subsidiary of Prestige Brands Holdings, Inc. for its Caldesene line of products, Insight Pharmaceuticals Llc, for its Caldesene line of products, Novartis Corporation (sued individually and as a successor-in-interest to CIBA-GEIGY Corporation and its subsidiaries CIBA Consumer Pharmaceuticals and CIBA Self-Medication, Inc.) for its Caldesene line of products, Prestige Brands Holdings, Inc. for its Caldesene line of products, Prestige Consumer Healthcare Inc. f/k/a Prestige Brands, Inc. for its Caldesene line of products, Pti Union, Llc a/k/a Pharma Tech Industries for its Gold Bond line of products, Revlon Consumer Products Corporation (sued individually and as successor-in-interest to Charles of the Ritz) for its Jean Nate line of products, Sanofi-Aventis U.S. Llc (sued individually and as successor-by-merger to Aventis Pharmaceuticals Inc.) for its Caldesene line of products, Sanofi Us Services, Inc. for its Caldesene line of products, Specialty Minerals Inc. (sued individually and as a subsidiary of Minerals Technologies Inc.), Wegmans Food Markets, Inc., Whittaker Clark & Daniels, Inc.Torts - Asbestos document preview
  • Jeffrey Campise, Christopher R Campise as executor of the estate of Jeffrey James Campise v. Arkema, Inc. f/k/a Pennwalt Corporation for its Caldesene line of products, Aventis Inc. for its Caldesene line of products, Avon Products, Inc., Barretts Minerals Inc., Block Drug Company, Inc. (sued individually and as successor-in-interest to The Gold Bond Sterilizing Powder Company a/k/a The Gold Bond Company) for its Gold Bond line of products, Block Drug Corporation (sued individually and as successor-in-interest to The Gold Bond Sterilizing Powder Company a/k/a The Gold Bond Company) for its Gold Bond line of products, Brenntag North America, Inc. (sued individually and as successor-in-interest to Mineral Pigment Solutions, Inc. and as successor-in-interest to Whittaker Clark & Daniels, Inc.), Brenntag Specialties Llc f/k/a Brenntag Specialties, Inc. f/k/a Mineral Pigment Solutions, Inc. (sued individually and as successor-in-interest to Whittaker Clark & Daniels, Inc.), Bristol-Myers Squibb Company (sued individually and as successor-in-interest to Charles of the Ritz) for its Jean Nate line of products), Chanel, Inc., Charles B. Chrystal Company, Inc., Chattem, Inc. a subsidiary of Sanofi-Aventis U.S. LLC (sued individually and as successor-in-interest to Block Drug Corporation, successor-in-interest to The Gold Bond Sterilizing Powder Company a/k/a The Gold Bond Company) for its Gold Bond line of products, Glaxosmithkline Llc (Sued Individually And As Successor-In-Interest To Block Drug Corporation, Successor-In-Interest To The Gold Bond Sterilizing Powder Company A/K/A The Gold Bond Company For Its Gold Bond Line Of Products And As Successor-In-Interest to Novartis Corporation and Novartis Consumer Health Inc. for its Caldesene line of products), Gsk Consumer Health, Inc. f/k/a Novartis Consumer Health, Inc. f/k/a CIBA Self-Medication, Inc. for its Caldesene line of products, Himmel Management Co. Llc A/K/A Himmel Group formerly d/b/a Martin Himmel, Inc. (sued individually and as successor-in-interest to Block Drug Corporation successor-in-interest to The Gold Bond Sterilizing Powder Company a/k/a The Gold Bond Company) for its Gold Bond line of products, Insight Pharmaceuticals Corporation a subsidiary of Prestige Brands Holdings, Inc. for its Caldesene line of products, Insight Pharmaceuticals Llc, for its Caldesene line of products, Novartis Corporation (sued individually and as a successor-in-interest to CIBA-GEIGY Corporation and its subsidiaries CIBA Consumer Pharmaceuticals and CIBA Self-Medication, Inc.) for its Caldesene line of products, Prestige Brands Holdings, Inc. for its Caldesene line of products, Prestige Consumer Healthcare Inc. f/k/a Prestige Brands, Inc. for its Caldesene line of products, Pti Union, Llc a/k/a Pharma Tech Industries for its Gold Bond line of products, Revlon Consumer Products Corporation (sued individually and as successor-in-interest to Charles of the Ritz) for its Jean Nate line of products, Sanofi-Aventis U.S. Llc (sued individually and as successor-by-merger to Aventis Pharmaceuticals Inc.) for its Caldesene line of products, Sanofi Us Services, Inc. for its Caldesene line of products, Specialty Minerals Inc. (sued individually and as a subsidiary of Minerals Technologies Inc.), Wegmans Food Markets, Inc., Whittaker Clark & Daniels, Inc.Torts - Asbestos document preview
  • Jeffrey Campise, Christopher R Campise as executor of the estate of Jeffrey James Campise v. Arkema, Inc. f/k/a Pennwalt Corporation for its Caldesene line of products, Aventis Inc. for its Caldesene line of products, Avon Products, Inc., Barretts Minerals Inc., Block Drug Company, Inc. (sued individually and as successor-in-interest to The Gold Bond Sterilizing Powder Company a/k/a The Gold Bond Company) for its Gold Bond line of products, Block Drug Corporation (sued individually and as successor-in-interest to The Gold Bond Sterilizing Powder Company a/k/a The Gold Bond Company) for its Gold Bond line of products, Brenntag North America, Inc. (sued individually and as successor-in-interest to Mineral Pigment Solutions, Inc. and as successor-in-interest to Whittaker Clark & Daniels, Inc.), Brenntag Specialties Llc f/k/a Brenntag Specialties, Inc. f/k/a Mineral Pigment Solutions, Inc. (sued individually and as successor-in-interest to Whittaker Clark & Daniels, Inc.), Bristol-Myers Squibb Company (sued individually and as successor-in-interest to Charles of the Ritz) for its Jean Nate line of products), Chanel, Inc., Charles B. Chrystal Company, Inc., Chattem, Inc. a subsidiary of Sanofi-Aventis U.S. LLC (sued individually and as successor-in-interest to Block Drug Corporation, successor-in-interest to The Gold Bond Sterilizing Powder Company a/k/a The Gold Bond Company) for its Gold Bond line of products, Glaxosmithkline Llc (Sued Individually And As Successor-In-Interest To Block Drug Corporation, Successor-In-Interest To The Gold Bond Sterilizing Powder Company A/K/A The Gold Bond Company For Its Gold Bond Line Of Products And As Successor-In-Interest to Novartis Corporation and Novartis Consumer Health Inc. for its Caldesene line of products), Gsk Consumer Health, Inc. f/k/a Novartis Consumer Health, Inc. f/k/a CIBA Self-Medication, Inc. for its Caldesene line of products, Himmel Management Co. Llc A/K/A Himmel Group formerly d/b/a Martin Himmel, Inc. (sued individually and as successor-in-interest to Block Drug Corporation successor-in-interest to The Gold Bond Sterilizing Powder Company a/k/a The Gold Bond Company) for its Gold Bond line of products, Insight Pharmaceuticals Corporation a subsidiary of Prestige Brands Holdings, Inc. for its Caldesene line of products, Insight Pharmaceuticals Llc, for its Caldesene line of products, Novartis Corporation (sued individually and as a successor-in-interest to CIBA-GEIGY Corporation and its subsidiaries CIBA Consumer Pharmaceuticals and CIBA Self-Medication, Inc.) for its Caldesene line of products, Prestige Brands Holdings, Inc. for its Caldesene line of products, Prestige Consumer Healthcare Inc. f/k/a Prestige Brands, Inc. for its Caldesene line of products, Pti Union, Llc a/k/a Pharma Tech Industries for its Gold Bond line of products, Revlon Consumer Products Corporation (sued individually and as successor-in-interest to Charles of the Ritz) for its Jean Nate line of products, Sanofi-Aventis U.S. Llc (sued individually and as successor-by-merger to Aventis Pharmaceuticals Inc.) for its Caldesene line of products, Sanofi Us Services, Inc. for its Caldesene line of products, Specialty Minerals Inc. (sued individually and as a subsidiary of Minerals Technologies Inc.), Wegmans Food Markets, Inc., Whittaker Clark & Daniels, Inc.Torts - Asbestos document preview
  • Jeffrey Campise, Christopher R Campise as executor of the estate of Jeffrey James Campise v. Arkema, Inc. f/k/a Pennwalt Corporation for its Caldesene line of products, Aventis Inc. for its Caldesene line of products, Avon Products, Inc., Barretts Minerals Inc., Block Drug Company, Inc. (sued individually and as successor-in-interest to The Gold Bond Sterilizing Powder Company a/k/a The Gold Bond Company) for its Gold Bond line of products, Block Drug Corporation (sued individually and as successor-in-interest to The Gold Bond Sterilizing Powder Company a/k/a The Gold Bond Company) for its Gold Bond line of products, Brenntag North America, Inc. (sued individually and as successor-in-interest to Mineral Pigment Solutions, Inc. and as successor-in-interest to Whittaker Clark & Daniels, Inc.), Brenntag Specialties Llc f/k/a Brenntag Specialties, Inc. f/k/a Mineral Pigment Solutions, Inc. (sued individually and as successor-in-interest to Whittaker Clark & Daniels, Inc.), Bristol-Myers Squibb Company (sued individually and as successor-in-interest to Charles of the Ritz) for its Jean Nate line of products), Chanel, Inc., Charles B. Chrystal Company, Inc., Chattem, Inc. a subsidiary of Sanofi-Aventis U.S. LLC (sued individually and as successor-in-interest to Block Drug Corporation, successor-in-interest to The Gold Bond Sterilizing Powder Company a/k/a The Gold Bond Company) for its Gold Bond line of products, Glaxosmithkline Llc (Sued Individually And As Successor-In-Interest To Block Drug Corporation, Successor-In-Interest To The Gold Bond Sterilizing Powder Company A/K/A The Gold Bond Company For Its Gold Bond Line Of Products And As Successor-In-Interest to Novartis Corporation and Novartis Consumer Health Inc. for its Caldesene line of products), Gsk Consumer Health, Inc. f/k/a Novartis Consumer Health, Inc. f/k/a CIBA Self-Medication, Inc. for its Caldesene line of products, Himmel Management Co. Llc A/K/A Himmel Group formerly d/b/a Martin Himmel, Inc. (sued individually and as successor-in-interest to Block Drug Corporation successor-in-interest to The Gold Bond Sterilizing Powder Company a/k/a The Gold Bond Company) for its Gold Bond line of products, Insight Pharmaceuticals Corporation a subsidiary of Prestige Brands Holdings, Inc. for its Caldesene line of products, Insight Pharmaceuticals Llc, for its Caldesene line of products, Novartis Corporation (sued individually and as a successor-in-interest to CIBA-GEIGY Corporation and its subsidiaries CIBA Consumer Pharmaceuticals and CIBA Self-Medication, Inc.) for its Caldesene line of products, Prestige Brands Holdings, Inc. for its Caldesene line of products, Prestige Consumer Healthcare Inc. f/k/a Prestige Brands, Inc. for its Caldesene line of products, Pti Union, Llc a/k/a Pharma Tech Industries for its Gold Bond line of products, Revlon Consumer Products Corporation (sued individually and as successor-in-interest to Charles of the Ritz) for its Jean Nate line of products, Sanofi-Aventis U.S. Llc (sued individually and as successor-by-merger to Aventis Pharmaceuticals Inc.) for its Caldesene line of products, Sanofi Us Services, Inc. for its Caldesene line of products, Specialty Minerals Inc. (sued individually and as a subsidiary of Minerals Technologies Inc.), Wegmans Food Markets, Inc., Whittaker Clark & Daniels, Inc.Torts - Asbestos document preview
  • Jeffrey Campise, Christopher R Campise as executor of the estate of Jeffrey James Campise v. Arkema, Inc. f/k/a Pennwalt Corporation for its Caldesene line of products, Aventis Inc. for its Caldesene line of products, Avon Products, Inc., Barretts Minerals Inc., Block Drug Company, Inc. (sued individually and as successor-in-interest to The Gold Bond Sterilizing Powder Company a/k/a The Gold Bond Company) for its Gold Bond line of products, Block Drug Corporation (sued individually and as successor-in-interest to The Gold Bond Sterilizing Powder Company a/k/a The Gold Bond Company) for its Gold Bond line of products, Brenntag North America, Inc. (sued individually and as successor-in-interest to Mineral Pigment Solutions, Inc. and as successor-in-interest to Whittaker Clark & Daniels, Inc.), Brenntag Specialties Llc f/k/a Brenntag Specialties, Inc. f/k/a Mineral Pigment Solutions, Inc. (sued individually and as successor-in-interest to Whittaker Clark & Daniels, Inc.), Bristol-Myers Squibb Company (sued individually and as successor-in-interest to Charles of the Ritz) for its Jean Nate line of products), Chanel, Inc., Charles B. Chrystal Company, Inc., Chattem, Inc. a subsidiary of Sanofi-Aventis U.S. LLC (sued individually and as successor-in-interest to Block Drug Corporation, successor-in-interest to The Gold Bond Sterilizing Powder Company a/k/a The Gold Bond Company) for its Gold Bond line of products, Glaxosmithkline Llc (Sued Individually And As Successor-In-Interest To Block Drug Corporation, Successor-In-Interest To The Gold Bond Sterilizing Powder Company A/K/A The Gold Bond Company For Its Gold Bond Line Of Products And As Successor-In-Interest to Novartis Corporation and Novartis Consumer Health Inc. for its Caldesene line of products), Gsk Consumer Health, Inc. f/k/a Novartis Consumer Health, Inc. f/k/a CIBA Self-Medication, Inc. for its Caldesene line of products, Himmel Management Co. Llc A/K/A Himmel Group formerly d/b/a Martin Himmel, Inc. (sued individually and as successor-in-interest to Block Drug Corporation successor-in-interest to The Gold Bond Sterilizing Powder Company a/k/a The Gold Bond Company) for its Gold Bond line of products, Insight Pharmaceuticals Corporation a subsidiary of Prestige Brands Holdings, Inc. for its Caldesene line of products, Insight Pharmaceuticals Llc, for its Caldesene line of products, Novartis Corporation (sued individually and as a successor-in-interest to CIBA-GEIGY Corporation and its subsidiaries CIBA Consumer Pharmaceuticals and CIBA Self-Medication, Inc.) for its Caldesene line of products, Prestige Brands Holdings, Inc. for its Caldesene line of products, Prestige Consumer Healthcare Inc. f/k/a Prestige Brands, Inc. for its Caldesene line of products, Pti Union, Llc a/k/a Pharma Tech Industries for its Gold Bond line of products, Revlon Consumer Products Corporation (sued individually and as successor-in-interest to Charles of the Ritz) for its Jean Nate line of products, Sanofi-Aventis U.S. Llc (sued individually and as successor-by-merger to Aventis Pharmaceuticals Inc.) for its Caldesene line of products, Sanofi Us Services, Inc. for its Caldesene line of products, Specialty Minerals Inc. (sued individually and as a subsidiary of Minerals Technologies Inc.), Wegmans Food Markets, Inc., Whittaker Clark & Daniels, Inc.Torts - Asbestos document preview
  • Jeffrey Campise, Christopher R Campise as executor of the estate of Jeffrey James Campise v. Arkema, Inc. f/k/a Pennwalt Corporation for its Caldesene line of products, Aventis Inc. for its Caldesene line of products, Avon Products, Inc., Barretts Minerals Inc., Block Drug Company, Inc. (sued individually and as successor-in-interest to The Gold Bond Sterilizing Powder Company a/k/a The Gold Bond Company) for its Gold Bond line of products, Block Drug Corporation (sued individually and as successor-in-interest to The Gold Bond Sterilizing Powder Company a/k/a The Gold Bond Company) for its Gold Bond line of products, Brenntag North America, Inc. (sued individually and as successor-in-interest to Mineral Pigment Solutions, Inc. and as successor-in-interest to Whittaker Clark & Daniels, Inc.), Brenntag Specialties Llc f/k/a Brenntag Specialties, Inc. f/k/a Mineral Pigment Solutions, Inc. (sued individually and as successor-in-interest to Whittaker Clark & Daniels, Inc.), Bristol-Myers Squibb Company (sued individually and as successor-in-interest to Charles of the Ritz) for its Jean Nate line of products), Chanel, Inc., Charles B. Chrystal Company, Inc., Chattem, Inc. a subsidiary of Sanofi-Aventis U.S. LLC (sued individually and as successor-in-interest to Block Drug Corporation, successor-in-interest to The Gold Bond Sterilizing Powder Company a/k/a The Gold Bond Company) for its Gold Bond line of products, Glaxosmithkline Llc (Sued Individually And As Successor-In-Interest To Block Drug Corporation, Successor-In-Interest To The Gold Bond Sterilizing Powder Company A/K/A The Gold Bond Company For Its Gold Bond Line Of Products And As Successor-In-Interest to Novartis Corporation and Novartis Consumer Health Inc. for its Caldesene line of products), Gsk Consumer Health, Inc. f/k/a Novartis Consumer Health, Inc. f/k/a CIBA Self-Medication, Inc. for its Caldesene line of products, Himmel Management Co. Llc A/K/A Himmel Group formerly d/b/a Martin Himmel, Inc. (sued individually and as successor-in-interest to Block Drug Corporation successor-in-interest to The Gold Bond Sterilizing Powder Company a/k/a The Gold Bond Company) for its Gold Bond line of products, Insight Pharmaceuticals Corporation a subsidiary of Prestige Brands Holdings, Inc. for its Caldesene line of products, Insight Pharmaceuticals Llc, for its Caldesene line of products, Novartis Corporation (sued individually and as a successor-in-interest to CIBA-GEIGY Corporation and its subsidiaries CIBA Consumer Pharmaceuticals and CIBA Self-Medication, Inc.) for its Caldesene line of products, Prestige Brands Holdings, Inc. for its Caldesene line of products, Prestige Consumer Healthcare Inc. f/k/a Prestige Brands, Inc. for its Caldesene line of products, Pti Union, Llc a/k/a Pharma Tech Industries for its Gold Bond line of products, Revlon Consumer Products Corporation (sued individually and as successor-in-interest to Charles of the Ritz) for its Jean Nate line of products, Sanofi-Aventis U.S. Llc (sued individually and as successor-by-merger to Aventis Pharmaceuticals Inc.) for its Caldesene line of products, Sanofi Us Services, Inc. for its Caldesene line of products, Specialty Minerals Inc. (sued individually and as a subsidiary of Minerals Technologies Inc.), Wegmans Food Markets, Inc., Whittaker Clark & Daniels, Inc.Torts - Asbestos document preview
  • Jeffrey Campise, Christopher R Campise as executor of the estate of Jeffrey James Campise v. Arkema, Inc. f/k/a Pennwalt Corporation for its Caldesene line of products, Aventis Inc. for its Caldesene line of products, Avon Products, Inc., Barretts Minerals Inc., Block Drug Company, Inc. (sued individually and as successor-in-interest to The Gold Bond Sterilizing Powder Company a/k/a The Gold Bond Company) for its Gold Bond line of products, Block Drug Corporation (sued individually and as successor-in-interest to The Gold Bond Sterilizing Powder Company a/k/a The Gold Bond Company) for its Gold Bond line of products, Brenntag North America, Inc. (sued individually and as successor-in-interest to Mineral Pigment Solutions, Inc. and as successor-in-interest to Whittaker Clark & Daniels, Inc.), Brenntag Specialties Llc f/k/a Brenntag Specialties, Inc. f/k/a Mineral Pigment Solutions, Inc. (sued individually and as successor-in-interest to Whittaker Clark & Daniels, Inc.), Bristol-Myers Squibb Company (sued individually and as successor-in-interest to Charles of the Ritz) for its Jean Nate line of products), Chanel, Inc., Charles B. Chrystal Company, Inc., Chattem, Inc. a subsidiary of Sanofi-Aventis U.S. LLC (sued individually and as successor-in-interest to Block Drug Corporation, successor-in-interest to The Gold Bond Sterilizing Powder Company a/k/a The Gold Bond Company) for its Gold Bond line of products, Glaxosmithkline Llc (Sued Individually And As Successor-In-Interest To Block Drug Corporation, Successor-In-Interest To The Gold Bond Sterilizing Powder Company A/K/A The Gold Bond Company For Its Gold Bond Line Of Products And As Successor-In-Interest to Novartis Corporation and Novartis Consumer Health Inc. for its Caldesene line of products), Gsk Consumer Health, Inc. f/k/a Novartis Consumer Health, Inc. f/k/a CIBA Self-Medication, Inc. for its Caldesene line of products, Himmel Management Co. Llc A/K/A Himmel Group formerly d/b/a Martin Himmel, Inc. (sued individually and as successor-in-interest to Block Drug Corporation successor-in-interest to The Gold Bond Sterilizing Powder Company a/k/a The Gold Bond Company) for its Gold Bond line of products, Insight Pharmaceuticals Corporation a subsidiary of Prestige Brands Holdings, Inc. for its Caldesene line of products, Insight Pharmaceuticals Llc, for its Caldesene line of products, Novartis Corporation (sued individually and as a successor-in-interest to CIBA-GEIGY Corporation and its subsidiaries CIBA Consumer Pharmaceuticals and CIBA Self-Medication, Inc.) for its Caldesene line of products, Prestige Brands Holdings, Inc. for its Caldesene line of products, Prestige Consumer Healthcare Inc. f/k/a Prestige Brands, Inc. for its Caldesene line of products, Pti Union, Llc a/k/a Pharma Tech Industries for its Gold Bond line of products, Revlon Consumer Products Corporation (sued individually and as successor-in-interest to Charles of the Ritz) for its Jean Nate line of products, Sanofi-Aventis U.S. Llc (sued individually and as successor-by-merger to Aventis Pharmaceuticals Inc.) for its Caldesene line of products, Sanofi Us Services, Inc. for its Caldesene line of products, Specialty Minerals Inc. (sued individually and as a subsidiary of Minerals Technologies Inc.), Wegmans Food Markets, Inc., Whittaker Clark & Daniels, Inc.Torts - Asbestos document preview 
						
                                
Preview

                                FILED: ERIE COUNTY CLERK 03/01/2023 08:59 PM         INDEX NO. 814239/2021
NYSCEF DOC. NO. 443                            RECEIVED NYSCEF: 03/01/2023




                      EXHIBIT
                        120
FILED: ERIE COUNTY CLERK 03/01/2023 08:59 PM                                             INDEX NO. 814239/2021
NYSCEF DOC. NO. 443                                                                RECEIVED NYSCEF: 03/01/2023
            ROBERT M. WEISS, PMK OF BRISTOL-MYERS SQUIBB COMPANY,· on 07/07/2016               Page 1
            POLAKOW, et al. vs. BRENNTAG NORTH AMERICA, INC., et al.


      ·1· · · · SUPERIOR COURT OF THE STATE OF CALIFORNIA

      ·2· · · · · · · FOR THE COUNTY OF LOS ANGELES

      ·3

      ·4·   ·Coordinated Proceedings· · · ·)·            JCCP NO. 4674
      · ·   ·Special Title (Rule 3.550)· · )
      ·5·   · · · · · · · · · · · · · · · ·)
      · ·   ·LAOSD ASBESTOS CASES· · · · · )
      ·6·   ·______________________________)
      · ·   · · · · · · · · · · · · · · · ·)
      ·7·   ·DANNIELLE ANN POLAKOW and· · ·)
      · ·   ·MICHAEL ELLIOT POLAKOW,· · · ·)·            LACSC CASE NO.
      ·8·   · · · · · · · · · · · · · · · ·)·            BC599542
      · ·   · · · · · Plaintiffs,· · · · · )
      ·9·   · · · · · · · · · · · · · · · ·)
      · ·   · · · vs.· · · · · · · · · · · )
      10·   · · · · · · · · · · · · · · · ·)
      · ·   ·BRENNTAG NORTH AMERICA, INC.· )
      11·   ·(sued individually and as· · ·)
      · ·   ·successor-in-interest to· · · )
      12·   ·MINERAL PIGMENT SOLUTIONS,· · )
      · ·   ·INC. as successor-in-interest )
      13·   ·to WHITTAKER, CLARK & DANIELS,)
      · ·   ·INC.), et al.,· · · · · · · · )
      14·   · · · · · · · · · · · · · · · ·)
      · ·   · · · · · Defendants.· · · · · )·            (Pages 1 - 393)
      15·   ·______________________________)

      16

      17

      18

      19

      20· · · · VIDEOTAPED DEPOSITION OF ROBERT M. WEISS

      21· · · · · ·PMK OF BRISTOL-MYERS SQUIBB COMPANY

      22· · · · · · · · · THURSDAY, JULY 7, 2016

      23

      24· ·REPORTED BY:· DEBRA G. JOHNSON-SPALLONE
      · · · · · · · · · ·CCR.· NO. NJ1182
      25



                                              323.393.3768 • 888.99.iDepo
                                               www.iDepoReporters.com
FILED: ERIE COUNTY CLERK 03/01/2023 08:59 PM                                                                                           INDEX NO. 814239/2021
NYSCEF DOC. NO. 443                                                                                                        RECEIVED NYSCEF: 03/01/2023
         ROBERT M. WEISS, PMK OF BRISTOL-MYERS SQUIBB COMPANY,· on 07/07/2016                                                              Pages 2–5
         POLAKOW, et al. vs. BRENNTAG NORTH AMERICA, INC., et al.
                                                                       Page 2                                                                 Page 4
           ·1· · · · SUPERIOR COURT OF THE STATE OF CALIFORNIA                  ·1· ·APPEARANCES:· (Continued)
           ·2· · · · · · · FOR THE COUNTY OF LOS ANGELES                        ·2
           ·3                                                                   ·3· · · · PEPPER HAMILTON, LLP
                                                                                · · · · · BY:· YEHUDAH GORDON, ESQ.
           ·4· ·Coordinated Proceedings· · · ·)· JCCP NO. 4674
                                                                                ·4· · · · 620 8th Avenue
           · · ·Special Title (Rule 3.550)· · )
                                                                                · · · · · 37th Floor
           ·5· · · · · · · · · · · · · · · · ·)
                                                                                ·5· · · · New York, NY 10018
           · · ·LAOSD ASBESTOS CASES· · · · · )
                                                                                · · · · · (212) 808-2719
           ·6· ·______________________________)                                 ·6· · · · gordony@pepperlaw.com
           · · · · · · · · · · · · · · · · · ·)                                 ·7· · · · · · · · · · · · · ·AND
           ·7· ·DANNIELLE ANN POLAKOW and· · ·)                                 ·8· · · · DLA PIPER, LLP
           · · ·MICHAEL ELLIOT POLAKOW,· · · ·)· LACSC CASE NO.                 · · · · · BY:· SEAN CRAIN, ESQ.
           ·8· · · · · · · · · · · · · · · · ·)· BC599542                       ·9· · · · 2000 Avenue of the Stars
                                                                                · · · · · Suite 400 North Tower
           · · · · · · · Plaintiffs,· · · · · )
                                                                                10· · · · Los Angeles, CA 90067
           ·9· · · · · · · · · · · · · · · · ·)
                                                                                · · · · · (310) 595-3025
           · · · · · vs.· · · · · · · · · · · )
                                                                                11· · · · sean.crain@dlapiper.com
           10· · · · · · · · · · · · · · · · ·)
                                                                                · · · · · (Telephonic Appearance)
           · · ·BRENNTAG NORTH AMERICA, INC.· )                                 12
           11· ·(sued individually and as· · ·)                                 13· ·For Defendant COLGATE-PALMOLIVE COMPANY and CYPRUS
           · · ·successor-in-interest to· · · )                                 · · ·AMAX MINERALS COMPANY (sued as successor to SIERRA
           12· ·MINERAL PIGMENT SOLUTIONS,· · )                                 14· ·TALC COMPANY and UNITED TALC COMPANY), (Via
           · · ·INC. as successor-in-interest )                                 · · ·Telephone):

           13· ·to WHITTAKER, CLARK & DANIELS,)                                 15
                                                                                16· · · · FOLEY & MANSFIELD PLLP
           · · ·INC.), et al.,· · · · · · · · )
                                                                                · · · · · BY:· KARLEEN F. MURPHY, ESQ.
           14· · · · · · · · · · · · · · · · ·)
                                                                                17· · · · 300 South Grand Avenue
           · · · · · · · Defendants.· · · · · )
                                                                                · · · · · Suite 2800
           15· ·______________________________)                                 18· · · · Los Angeles, CA 90071
           16· · · · · · ·Videotaped Deposition of ROBERT M. WEISS,             · · · · · (213) 283-2100
           17· ·taken on behalf of Plaintiffs at PEPPER HAMILTON,               19· · · · kmurphy@foleymansfield.com
           18· ·301 Carnegie Center, Princeton, New Jersey                      20· · · · · · · · · · · · · ·AND
           19· ·08540-6589, commencing at 10:19 a.m., Thursday,                 21· · · · FOLEY & MANSFIELD, PLLP
                                                                                · · · · · BY:· J. SCOTT WOOD, ESQ.
           20· ·July 7, 2016, before DEBRA G. JOHNSON-SPALLONE,
                                                                                22· · · · 999 Third Avenue
           21· ·CCR, RPR, Delaware CSR, Notary Public in and for
                                                                                · · · · · Suite 3760
           22· ·the States of New Jersey, Pennsylvania and
                                                                                23· · · · Seattle, WA 98104
           23· ·Delaware, and a Federally Approved Reporter of the
                                                                                · · · · · (206) 456-5360
           24· ·United States District Court.                                   24· · · · swood@foleymansfield.com
           25                                                                   25


                                                                       Page 3                                                                 Page 5
           ·1· ·APPEARANCES:                                                    ·1· ·APPEARANCES:· (Continued)
           ·2                                                                   ·2
           ·3· ·For Plaintiffs, DANNIELLE ANN POLAKOW and MICHAEL               · · ·For Defendant, THE W.W. HENRY COMPANY (Via
           · · ·ELLIOT POLAKOW:                                                 ·3· ·Telephone):
           ·4                                                                   ·4
           ·5· · · · SIMON GREENSTONE PANATIER & BARTLETT, PC                   · · · · · LEWIS BRISBOIS BISGAARD & SMITH, LLP
           · · · · · BY:· LEAH C. KAGAN, ESQ.                                   ·5· · · · BY:· JUDIEE L. PINKERTON, ESQ.
           ·6· · · · 3780 Kilroy Airport Way                                    · · · · · 333 Bush Street
           · · · · · Suite 540                                                  ·6· · · · Suite 1100
           ·7· · · · Long Beach, CA 90806                                       · · · · · San Francisco, CA 94104
           · · · · · (562) 590-3400                                             ·7· · · · (415) 532-2580

           ·8· · · · lkagan@sgpblaw.com                                         · · · · · judiee.pinkerton@lewisbrisbois.com

           ·9                                                                   ·8
                                                                                ·9
           10· ·For Defendant, BRISTOL-MYERS SQUIBB, YVES SAINT
                                                                                · · ·For Defendant, IMERYS USA (sued individually and as
           · · ·LAURENT AMERICA, INC., a subsidiary of KERING
                                                                                10· ·successor-in-interest to LUZENAC AMERICA, INC.,
           11· ·HOLLAND NV and REVLON, INC.:
                                                                                · · ·successor-in-interest to CYPRUS INDUSTRIAL MINERALS
           12
                                                                                11· ·COMPANY)(Via Telephone):
           · · · · · HAWKINS PARNELL THACKSTON & YOUNG, LLP
                                                                                12
           13· · · · BY:· EDWARD R. ULLOA, ESQ.
                                                                                · · · · · DENTONS US LLP
           · · · · · 445 South Figueroa Street
                                                                                13· · · · BY:· CAREN DOMBROWSKI, ESQ.
           14· · · · Suite 3200
                                                                                · · · · · 601 South Figueroa Street
           · · · · · Los Angeles, CA 90071
                                                                                14· · · · Suite 2500
           15· · · · (213) 486-8000
                                                                                · · · · · Los Angeles, CA 90071
           · · · · · eulloa@hptylaw.com
                                                                                15· · · · (213) 623-9300
           16
                                                                                · · · · · caren.dombrowski@dentons.com
           · · · · · · · · · · · · · · ·AND
                                                                                16
           17
                                                                                17· ·For Defendant, CHANEL, INC., (Via Telephone):
           · · · · · HAWKINS PARNELL THACKSTON & YOUNG, LLP
                                                                                18
           18· · · · BY:· EDWARD P. ABBOT, ESQ.                                 · · · · · MANION GAYNOR & MANNING, LLP
           · · · · · 600 Lexington Avenue                                       19· · · · BY:· NICOLE A. HARRISON, ESQ.
           19· · · · 8th Floor                                                  · · · · · · · ·LINDSAY WEISS, ESQ.
           · · · · · New York, NY 10022                                         20· · · · 444 South Flower Street
           20· · · · (212) 897-9655                                             · · · · · Suite 2150
           · · · · · eabbot@hptylaw.com                                         21· · · · Los Angeles, CA 90071
           21                                                                   · · · · · (213) 694-4207
           · · · · · · · · · · · · · · ·AND                                     22· · · · nharris@mgmlaw.com
           22                                                                   · · · · · lweiss@mgmlaw.com
           23                                                                   23
           24                                                                   24
           25                                                                   25




                                                              323.393.3768 • 888.99.iDepo
                                                               www.iDepoReporters.com
FILED: ERIE COUNTY CLERK 03/01/2023 08:59 PM                                                                                           INDEX NO. 814239/2021
NYSCEF DOC. NO. 443                                                                                                       RECEIVED NYSCEF: 03/01/2023
         ROBERT M. WEISS, PMK OF BRISTOL-MYERS SQUIBB COMPANY,· on 07/07/2016                                                              Pages 6–9
         POLAKOW, et al. vs. BRENNTAG NORTH AMERICA, INC., et al.
                                                                      Page 6                                                                  Page 8
           ·1· ·APPEARANCES:· (Continued)                                      ·1· ·INDEX:· ·(Continued),
           ·2
                                                                               ·2· ·Exhibit-3· · ·Minutes of Special Meeting· · · 82
           · · ·For Defendant, BRENNTAG SPECIALTIES, INC., and
           ·3· ·Specially appearing pursuant to an                             ·3· · · · · · of Stockholders of Lanvin-
           · · ·agreement/stipulation with Leah Kegan, Esq., for
                                                                               ·4· · · · · · Charles of the Ritz, Inc.
           ·4· ·WHITTAKER CLARK & DANIELS, INC., and BRENNTAG NORTH
           · · ·AMERICA, INC. (Via Telephone):                                 ·5· ·Exhibit-4· · ·Purchase Agreement· · · · · · ·105
           ·5
                                                                               ·6· ·Exhibit-5· · ·Affidavit· · · · · · · · · · · 118
           ·6· · · · MURRIN & ASSOCIATES LLC
           · · · · · BY:· REYNOLD M. MARTINEZ, ESQ.                            ·7· ·Exhibit-6· · ·Cyprus Industrial Minerals· · ·178
           ·7· · · · 3675 Mount Diablo Boulevard
                                                                               ·8· ·Exhibit-7· · ·Customer Specification· · · · ·198
           · · · · · Suite 230
           ·8· · · · Lafayette, CA 94549                                       ·9· · · · · · Sheet for Charles of the
           · · · · · (925) 284-5770
                                                                               10· · · · · · Ritz Group, Ltd.
           ·9· · · · reynold.martinez@murrinlaw.net
           10                                                                  11· ·Exhibit-8· · ·Customer Specification· · · · ·203
           11· ·For Defendant, Franklin's Hardware (Via Telephone):
                                                                               12· · · · · · Sheet for Bristol-Myers
           12
           · · · · · WFBM, LLP                                                 13· · · · · · Company, International
           13· · · · BY:· HAARIS SHAHZAD, ESQ.
                                                                               14· · · · · · Division
           · · · · · 707 Wilshire Boulevard
           14· · · · Suite 3280                                                15· ·Exhibit-9· · ·Membership List - CTFA· · · · ·215
           · · · · · Los Angeles, CA 90017
                                                                               16· · · · · · Talc Subcommittee
           15· · · · (213) 489-4820
           · · · · · hshahzad@wfbm.com                                         17· ·Exhibit-10· · 1967, Contents· · · · · · · · ·220
           16
           17                                                                  18· ·Exhibit-11· · Affidavit of Custodian of· · · 226

           · · ·ALSO PRESENT:                                                  19· · · · · · Records of the Dallas
           18
           · · ·SUSAN FARKAS, SENIOR CORPORATE COUNSEL                         20· · · · · · Public Library

           19· ·BRISTOL-MYERS SQUIBB COMPANY                                   21· ·Exhibit-12· · Affidavit of Document· · · · · 226
           20· ·SHIVANG GANDHI, LEGAL INTERN
           · · ·BRISTOL-MYERS SQUIBB                                           22· · · · · · Authentication

           21                                                                  23
           22
           23                                                                  24

           24
                                                                               25
           25


                                                                      Page 7                                                                  Page 9
           ·1· · · · · · · · · · · · I N D E X                                 ·1· ·INDEX (Continued)

           ·2· ·DEPONENT:· · · · ·EXAMINATION· · · · · · PAGE:                 ·2· ·Exhibit-13· · Division of Color and· · · · · 232

           ·3· ·ROBERT M. WEISS                                                ·3· · · · · · Cosmetics Technology,

           ·4· · · · BY MS. KAGAN· · · · · · · · · · · · · ·15                 ·4· · · · · · Food and Drug Administration,

           ·5· · · · BY MR. ULLOA· · · · · · · · · · · · · 387                 ·5· · · · · · Washington, D.C., Discussion

           ·6                                                                  ·6· · · · · · Session of Asbestos and Talc

           ·7                                                                  ·7· ·Exhibit-14· · Talc Analysis (Asbestos)· · · ·249

           ·8· · · · · · · · · · · · ·EXHIBITS                                 ·8· ·Exhibit-15· · A letter from Seymour Z.· · · ·254

           ·9· ·MARKED· · · · · · · · · · · · · · · · · ·PAGE                  ·9· · · · · · Lewin to Dr. Alfred

           10· ·Exhibit-1· · ·Plaintiffs' Second Amended· · 17                 10· · · · · · Weissler dated August 3,

           11· · · · · · Notice of Taking the                                  11· · · · · · 1972

           12· · · · · · Videotaped Deposition of                              12· ·Exhibit-16· · A letter from Seymour Z.· · · ·260

           13· · · · · · "Person Most Knowledgeable"                           13· · · · · · Lewin to Mr. George J.

           14· · · · · · of Defendant Bristol-Myers                            14· · · · · · Dippold dated September

           15· · · · · · Squibb Company (sued                                  15· ·Exhibit-17· · A memorandum to Mr. J.E.· · · ·265

           16· · · · · · individually and as                                   16· · · · · · Clements from Mr. H.D.

           17· · · · · · successor-in-interest to                              17· · · · · · Stanley dated December 8,

           18· · · · · · Charles of the Ritz) and                              18· · · · · · 1972

           19· · · · · · Request for Production of                             19· ·Exhibit-18· · A memorandum to Dr. Robert· · ·274

           20· · · · · · Documents                                             20· · · · · · M. Schaffner from

           21· ·Exhibit-2· · ·Defendant Bristol-Myers· · · ·47                 21· · · · · · Dr. Alfred Weissler dated

           22· · · · · · Squibb Company's Responses                            22· · · · · · July 31, 1973

           23· · · · · · to Plaintiffs' Standard                               23

           24· · · · · · Interrogatories                                       24

           25                                                                  25




                                                            323.393.3768 • 888.99.iDepo
                                                             www.iDepoReporters.com                                                                    YVer1f
FILED: ERIE COUNTY CLERK 03/01/2023 08:59 PM                                                                                         INDEX NO. 814239/2021
NYSCEF DOC. NO. 443                                                                                                      RECEIVED NYSCEF: 03/01/2023
         ROBERT M. WEISS, PMK OF BRISTOL-MYERS SQUIBB COMPANY,· on 07/07/2016                                                            Pages 10–13
         POLAKOW, et al. vs. BRENNTAG NORTH AMERICA, INC., et al.
                                                                    Page 10                                                                  Page 12
           ·1· ·INDEX (Continued)                                             ·1· · · · · · · · INFORMATION TO BE SUPPLIED

           ·2· ·Exhibit-19· · Meeting Minutes from the· · 281                 ·2· ·PAGE LINE

           ·3· · · · · · Cosmetic, Toiletry and                               ·3· ·76· ·22

           ·4· · · · · · Fragrance Association,                               ·4· ·Going to call for production of these Squibb

           ·5· · · · · · Inc., dated October 11,                              ·5· ·Physician's Desk References

           ·6· · · · · · 1973                                                 ·6· ·134· 12

           ·7· ·Exhibit-20· · A letter from George W.· · ·287                 ·7· ·I'm going to call for the production of the

           ·8· · · · · · Sandland to Mr. Fred                                 ·8· ·deposition transcript from the approximately 2013

           ·9· · · · · · Roesch dated October 19,                             ·9· ·deposition and the 2008 deposition

           10· · · · · · 1973                                                 10· ·375· 13

           11· ·Exhibit-21· · Memorandum of Meeting,· · · 302                 11· ·I'm going to call for the production of all

           12· · · · · · January 7, 1975                                      12· ·industrial hygiene program documents for Squibb and

           13· ·Exhibit-22· · Meeting Notes of CTFA· · · ·309                 13· ·for Bristol-Myers, and for Bristol-Myers Squibb

           14· · · · · · Talc Subcommittee,                                   14· ·dating back to as far as they go

           15· · · · · · Meeting Date:· February                              15· ·384· 18

           16· · · · · · 4, 1973                                              16· ·I am going to call for the production of all

           17· ·Exhibit-23· · A page of handwritten· · · ·314                 17· ·documents related to the worker's compensation

           18· · · · · · notes                                                18· ·claims made or workers exposed to asbestos at

           19· ·Exhibit-24· · A letter to Dr. Norman· · · 320                 19· ·Bristol-Myers Squibb, Squibb, Bristol-Myers,

           20· · · · · · Estrin from Ian M.                                   20· ·Charles of the Ritz

           21· · · · · · Stewart dated March 1,                               21· · · · · · · · · · · · · - - -

           22· · · · · · 1976                                                 22· · · · · · QUESTIONS INSTRUCTED NOT TO ANSWER

           23                                                                 23· ·PAGE LINE

           24                                                                 24· ·101· ·5

           25                                                                 25· ·I'm going to instruct not to answer



                                                                    Page 11                                                                  Page 13
           ·1· ·INDEX (Continued)
                                                                              ·1· · · · · · · · · · · · · - - -
           ·2· ·Exhibit-25· · A memorandum to Robert M.· · · 323
                                                                              ·2· · · · · · · · · ·PRINCETON, NEW JERSEY
           ·3· · · · · · Shaffner from Director,
                                                                              ·3· · · · · · · · · THURSDAY, JULY 7, 2016
           ·4· · · · · · Division of Cosmetic
                                                                              ·4· · · · · · · · · · · ·10:19 A.M.
           ·5· · · · · · Technology dated March 18,
                                                                              ·5· · · · · · · · · · · · ·- - - -
           ·6· · · · · · 1976
                                                                              ·6· · · · · ·VIDEO TECHNICIAN:· Stand by.
           ·7· ·Exhibit-26· · The Cosmetic, Toiletry and· · ·333
                                                                              ·7· · · · · ·Good morning.
           ·8· · · · · · Fragrance Association, Inc.,
                                                                              ·8· · · · · ·We are now recording, and on the record.
           ·9· · · · · · Minutes, CTFA Talc
                                                                              ·9· · · · · ·My name is Larry Moskowitz.· I am -- I am
           10· · · · · · Subcommittee, Meeting held
                                                                              10· ·the legal video specialist for iDepo Reporters.
           11· · · · · · July 8th, 1976
                                                                              11· ·Our business address is 898 North Sepulveda
           12· ·Exhibit-27· · A letter to Norman F. Estrin· ·341
                                                                              12· ·Boulevard, Suite 750, El Sequndo, California.
           13· · · · · · from Harold D. Stanley dated
                                                                              13· · · · · ·I'm not related to any party in this action,
           14· · · · · · August 18, 1976
                                                                              14· ·nor am I financially interested in the outcome in
           15· ·Exhibit-28· · Walter C. McCrone Associates,· 348
                                                                              15· ·anyway.
           16· · · · · · Inc., Date 9 November 1999,
                                                                              16· · · · · ·Today's date is July 7th, 2016, and the time
           17· · · · · · Client Colgate-Palmolive
                                                                              17· ·is 10:19 a.m.
           18· · · · · · Company
                                                                              18· · · · · ·This is the deposition of Robert Weiss in
           19· ·Exhibit-29· · A memorandum to S. Shope· · · ·355
                                                                              19· ·the matter of Danielle Ann Polakow, et al, versus
           20· · · · · · from F.W. Nebus dated
                                                                              20· ·Brenntag North America in -- in the Superior Court
           21· · · · · · November 1, 1979
                                                                              21· ·of the State of California, County of Los Angeles.
           22· ·Exhibit-30· · Pneumonoconiosis due to Talc· ·361
                                                                              22· · · · · ·This deposition is being taken at Pepper
           23· · · · · · in the Cosmetic Industry
                                                                              23· ·Hamilton, 301 Carnegie Center, Princeton, New
           24· ·Exhibit-31· · Chapter 88, Law of 1944· · · · 367
                                                                              24· ·Jersey on behalf of the Plaintiff.
           25
                                                                              25· · · · · ·The court reporter is Debra Johnson, also


                                                            323.393.3768 • 888.99.iDepo
                                                             www.iDepoReporters.com                                                                    YVer1f
FILED: ERIE COUNTY CLERK 03/01/2023 08:59 PM                                                                                     INDEX NO. 814239/2021
NYSCEF DOC. NO. 443                                                                                                  RECEIVED NYSCEF: 03/01/2023
         ROBERT M. WEISS, PMK OF BRISTOL-MYERS SQUIBB COMPANY,· on 07/07/2016                                                          Pages 14–17
         POLAKOW, et al. vs. BRENNTAG NORTH AMERICA, INC., et al.
                                                                      Page 14                                                              Page 16
           ·1· ·with iDepo Reporters.                                           ·1· ·Squibb Company.
           ·2· · · · · ·Will counsel please introduce themselves for            ·2· ·Q.· · · So, you are the Associate Director of
           ·3· ·the record?                                                     ·3· ·Regional Projects?
           ·4· · · · · ·MS. KAGAN:· Leah Kagan, Simon Greenstone                ·4· ·A.· · · Yes.
           ·5· ·Panatier Bartlett.· Counsel for the Polakow's.                  ·5· · · · · ·I recently transitioned between jobs within
           ·6· · · · · ·MR. ULLOA:· Ed Ulloa, Hawkins Parnell                   ·6· ·the company.· I had been the Associate Director for
           ·7· ·Thackston and Young.· Counsel for Bristol-Myers                 ·7· ·EHS at the New Brunswick, New Jersey facility.
           ·8· ·Squibb, Revlon, and Yves Saint Laurent.                         ·8· ·Q.· · · And what is EHS?
           ·9· · · · · ·MR. ABBOT:· Edward Abbot, Hawkins Parnell               ·9· ·A.· · · Environment, Health and Safety.
           10· ·Thackston and Young.· Counsel for Revlon,                       10· · · · · · · · · · · · ·(Pause)
           11· ·Bristol-Myers Squibb, and Yves Saint Laurent.                   11· ·Q.· · · How long, Mr. Weiss, have you worked for
           12· · · · · ·MR. GORDON:· Yehudah Gordon, Pepper                     12· ·Bristol-Myers Squibb?
           13· ·Hamilton.· Counsel for Bristol-Myers Squibb.                    13· ·A.· · · I have worked for Bristol-Myers Squibb
           14· · · · · ·VIDEO TECHNICIAN:· Will counsel on the phone            14· ·Company for almost 40 years.· I began my employ
           15· ·please introduce themselves for the record?                     15· ·with Squibb in 1976.· October of 1976.
           16· · · · · ·MS. MURPHY:· Karleen Murphy on behalf of                16· ·Q.· · · You understand that you are serving as the
           17· ·Colgate Palmolive Company.                                      17· ·corporate representative today for Bristol-Myers
           18· · · · · ·MR. MARTINEZ:· Good morning.                            18· ·Squibb in the Polakow matter; right?
           19· · · · · ·Reynold Martinez for Brenntag Specialties.              19· ·A.· · · Yes.
           20· · · · · ·MR. SHAHZAD:· Good morning.                             20· ·Q.· · · And you understand that the testimony you
           21· · · · · ·Haaris Shahzad on behalf of Franklin's                  21· ·offer today is binding on Bristol-Myers Squibb?
           22· ·Hardware.                                                       22· ·A.· · · Yes.
           23· · · · · ·MS. PINKERTON:· Good morning.                           23· ·Q.· · · And you understand that you are under oath;
           24· · · · · ·Judiee Pinkerton on behalf of the W.W. Henry            24· ·right?
           25· ·Company.                                                        25· ·A.· · · Yes.

                                                                      Page 15                                                              Page 17
           ·1· · · · · ·MR. WOOD:· Scott Wood on behalf of Cyprus               ·1· ·Q.· · · And that this video may be shown to a jury?
           ·2· ·Amax Minerals Company.                                          ·2· ·A.· · · Yes.
           ·3· · · · · ·MR. CRAIN:· Good morning.                               ·3· ·Q.· · · I'm going to hand you what I have marked as
           ·4· · · · · ·Sean Crain on behalf of Yves Saint Laurent              ·4· ·Exhibit-1.
           ·5· ·America, Inc.                                                   ·5· · · · · · · · · · · · · - - -
           ·6· · · · · ·MS. DOMBROWSKI:· Caren Dombrowski on behalf             ·6· · · · · ·(At which time Plaintiffs' Second
           ·7· ·of Imerys.                                                      ·7· · · · · ·Amended Notice of Taking the Videotaped
           ·8· · · · · ·VIDEO TECHNICIAN:· Will the reporter please             ·8· · · · · ·Deposition of "Person Most
           ·9· ·administer the oath?                                            ·9· · · · · ·Knowledgeable" of Defendant
           10· · · · · · · · · · · · ·- - - -                                   10· · · · · ·Bristol-Myers Squibb Company (sued
           11· · · · · ·ROBERT WEISS, after having been first duly              11· · · · · ·individually and as
           12· ·sworn as a witness, testified as follows:                       12· · · · · ·successor-in-interest to Charles of the
           13· · · · · · · · · · · · ·- - - -                                   13· · · · · ·Ritz) and Request for Production of
           14· · · · · · · · · · · ·EXAMINATION                                 14· · · · · ·Documents was received and marked as
           15· · · · · · · · · · · · ·- - - -                                   15· · · · · ·Deposition Exhibit 1 for identification
           16· ·BY MS. KAGAN:                                                   16· · · · · ·by counsel.)
           17· ·Q.· · · Good morning.                                           17· · · · · · · · · · · · · - - -
           18· ·A.· · · Good morning.                                           18· · · · · ·MR. ULLOA:· Leah, this is the Second Amended
           19· ·Q.· · · My name is Leah Kagan.                                  19· ·Notice of this previous deposition.· We previously
           20· · · · · ·I briefly introduced myself, excuse me, off             20· ·received a prior notice, and I think this one just
           21· ·the record.                                                     21· ·changes the date?
           22· · · · · ·Could you please introduce yourself for the             22· · · · · ·MS. KAGAN:· There is also additional
           23· ·jury?                                                           23· ·document requests in this one.
           24· ·A.· · · Robert M. Weiss, W-E-I-S-S, Associate                   24· · · · · ·MR. ULLOA:· Which one?
           25· ·Director, EHS Regional Projects for Bristol-Myers               25· · · · · ·MS. KAGAN:· It's the last one.


                                                     323.393.3768 • 888.99.iDepo
                                                      www.iDepoReporters.com                                                                         YVer1f
FILED: ERIE COUNTY CLERK 03/01/2023 08:59 PM                                                                                        INDEX NO. 814239/2021
NYSCEF DOC. NO. 443                                                                                                         RECEIVED NYSCEF: 03/01/2023
         ROBERT M. WEISS, PMK OF BRISTOL-MYERS SQUIBB COMPANY,· on 07/07/2016                                                            Pages 246–249
         POLAKOW, et al. vs. BRENNTAG NORTH AMERICA, INC., et al.
                                                                       Page 246                                                               Page 248
           ·1· ·90 to 95 percent certain."                                        ·1· ·BY MS. KAGAN:
           ·2· · · · · ·Do you see that?                                          ·2· ·Q.· · · So, Bristol-Myers has no knowledge as to
           ·3· ·A.· · · Yes.                                                      ·3· ·whether or not that specific technology was
           ·4· ·Q.· · · Does Bristol-Myers have a position one way                ·4· ·available after August, 1971 --
           ·5· ·or the other about the efficacy of electron                       ·5· · · · · ·MR. ULLOA:· Misstates prior testimony.
           ·6· ·microscopy in the identification of asbestos in                   ·6· · · · · ·Lacks foundation.
           ·7· ·talc?                                                             ·7· · · · · ·MS. KAGAN:· -- right?
           ·8· · · · · ·MR. ULLOA:· Calls for speculation.                        ·8· · · · · ·THE WITNESS:· Correct.
           ·9· · · · · ·Lacks foundation.                                         ·9· · · · · · · · · · · · · - - -
           10· · · · · ·Beyond the scope of the witness'                          10· ·CONTINUATION
           11· ·designation.                                                      11· ·BY MS. KAGAN:
           12· · · · · ·THE WITNESS:· No.                                         12· ·Q.· · · Okay.
           13· · · · · ·However, the technology has changed, and                  13· · · · · ·So, that was Dr. Langer's presentation, and
           14· ·it's now polarized electron microscopy.                           14· ·in response, Dr. Geiger's presentation from McCrone
           15· · · · · ·So, the techniques for identifying asbestos               15· ·was -- was characterized as a smokescreen to combat
           16· ·have changed slightly over the years to get a                     16· ·Art Langer's identification of chrysotile
           17· ·better identification.                                            17· ·fibrils --
           18· · · · · ·In this document itself, you have,                        18· · · · · ·MR. ULLOA:· Asked and answered.
           19· ·basically, both Langer's and McCrone's views on                   19· · · · · ·MS. KAGAN:· -- right?
           20· ·materials, and I just find that interesting.                      20· · · · · ·THE WITNESS:· Yes, it appears that way.
           21· · · · · ·I hadn't seen these.                                      21· · · · · ·MS. KAGAN:· Okay.
           22· · · · · · · · · · · · · - - -                                      22· · · · · ·We can put that aside.
           23· ·CONTINUATION                                                      23· · · · · ·I am going to hand you what I have marked as
           24· ·BY MS. KAGAN:                                                     24· ·Exhibit-14.
           25· ·Q.· · · Is it Bristol-Myers' position that as of                  25· · · · · · · · · · · · · - - -

                                                                       Page 247                                                               Page 249
           ·1· ·August 11th, 1971 --                                              ·1· · · · · ·(At which time Talc Analysis (Asbestos)
           ·2· ·A.· · · Sorry.                                                    ·2· · · · · ·was received and marked as Deposition
           ·3· ·Q.· · · -- polarized microscopy wasn't available for              ·3· · · · · ·Exhibit 14 for identification by
           ·4· ·analysis?                                                         ·4· · · · · ·counsel.)
           ·5· · · · · ·MR. ULLOA:· Misstates prior testimony.                    ·5· · · · · · · · · · · · · - - -
           ·6· · · · · ·Argumentative as phrased.                                 ·6· · · · · ·MR. ULLOA:· 14 for real?
           ·7· · · · · ·THE WITNESS:· I don't know when the                       ·7· · · · · ·MS. KAGAN:· 14 for real.
           ·8· ·technology changed.                                               ·8· · · · · ·MR. ULLOA:· Okay.
           ·9· · · · · ·I do know that it has changed slightly.                   ·9· · · · · ·MS. KAGAN:· For the record, this is Bates
           10· · · · · ·So, I don't believe it is a straight EM now.              10· ·number WCD 002478 through -- the last page doesn't
           11· · · · · ·It's polarized.                                           11· ·have a Bates number on it, but the second to the
           12· · · · · ·MS. KAGAN:· --                                            12· ·last page is 2481, but I think it is because it is
           13· · · · · ·THE WITNESS:· So, I believe that gives you a              13· ·one, long copy.· So, it's really one, long page
           14· ·better definition.                                                14· ·broken up into two.· It will make sense when --
           15· · · · · · · · · · · · · - - -                                      15· ·when you see it.
           16· ·CONTINUATION                                                      16· · · · · ·MR. ULLOA:· Okay.
           17· ·BY MS. KAGAN:                                                     17· · · · · · · · · · · · · - - -
           18· ·Q.· · · And my question was, sitting here today                   18· ·CONTINUATION
           19· ·Bristol-Myers has no knowledge of when polarized                  19· ·BY MS. KAGAN:
           20· ·microscopy was available as a technology for use in               20· ·Q.· · · Take a look, and let me know if you have
           21· ·identifying asbestos in talc; right?                              21· ·seen this document before.
           22· ·A.· · · Correct.                                                  22· ·A.· · · I have not seen this document.
           23· · · · · ·MR. ULLOA:· Asked and answered.                           23· ·Q.· · · I will represent to you that based on the
           24· · · · · · · · · · · · · - - -                                      24· ·Bates number this was a document that was produced
           25· ·CONTINUATION                                                      25· ·by Whittaker, Clark and Daniels, a distributor of



                                                        323.393.3768 • 888.99.iDepo
                                                         www.iDepoReporters.com                                                                          YVer1f
FILED: ERIE COUNTY CLERK 03/01/2023 08:59 PM                                                                                  INDEX NO. 814239/2021
NYSCEF DOC. NO. 443                                                                                                RECEIVED NYSCEF: 03/01/2023
         ROBERT M. WEISS, PMK OF BRISTOL-MYERS SQUIBB COMPANY,· on 07/07/2016                                                    Pages 250–253
         POLAKOW, et al. vs. BRENNTAG NORTH AMERICA, INC., et al.
                                                                   Page 250                                                               Page 252
           ·1· ·minerals and pigments to the cosmetic industry,               ·1· · · · · ·Well, let's not worry about those last pages
           ·2· ·and we've seen them identified so far in the CTFA             ·2· ·then.
           ·3· ·documents, and in the document we just looked at,             ·3· · · · · ·Now, we talked about reviewing the documents
           ·4· ·Exhibit-13; right?                                            ·4· ·from Cyprus, and those customer specification
           ·5· ·A.· · · Yeah.                                                 ·5· ·sheets I presented to you that Supra was Italian
           ·6· ·Q.· · · Now, the first page is sort of like a                 ·6· ·talc.
           ·7· ·worksheet and it's titled, "Talc Analysis                     ·7· · · · · ·Do you remember that?
           ·8· ·(Asbestos)."                                                  ·8· ·A.· · · Yes.
           ·9· · · · · ·Do you see that?                                      ·9· ·Q.· · · And here, this is a 1972, June, 1972,
           10· ·A.· · · Yes.                                                  10· ·positive identification of one percent chrysotile
           11· ·Q.· · · And it identifies product number 1615.                11· ·in talc from it.
           12· · · · · ·Do you see that?                                      12· · · · · ·Do you see that?
           13· ·A.· · · Yes.                                                  13· · · · · ·MR. ULLOA:· Calls for speculation.
           14· ·Q.· · · Product origin is Italy; right?                       14· · · · · ·Lacks foundation.
           15· ·A.· · · Yes.                                                  15· · · · · ·Lacks knowledge.
           16· ·Q.· · · The date is June 12, 1972; right?                     16· · · · · ·If you know.
           17· ·A.· · · Yes.                                                  17· · · · · ·I think she is asking you, does it say that?
           18· ·Q.· · · And then it has, work performed by ES                 18· · · · · ·THE WITNESS:· Yes, it says that.
           19· ·Laboratories.                                                 19· · · · · · · · · · · · · - - -
           20· · · · · ·Do you see that?                                      20· ·CONTINUATION
           21· ·A.· · · Yes.                                                  21· ·BY MS. KAGAN:
           22· ·Q.· · · And then it has Invoice Number 1428; right?           22· ·Q.· · · Did Bristol-Myers receive this test result
           23· ·A.· · · Yes.                                                  23· ·in 1972?
           24· ·Q.· · · And then under the next section, X-Ray                24· · · · · ·MR. ULLOA:· Calls for speculation.
           25· ·Diffraction Analysis (Percent).                               25· · · · · ·Vague.

                                                                   Page 251                                                               Page 253
           ·1· · · · · ·Do you see that under chrysotile it                   ·1· · · · · ·THE WITNESS:· I do not know.
           ·2· ·identifies one percent?                                       ·2· · · · · ·I also do not know if this material was
           ·3· ·A.· · · Yes.                                                  ·3· ·received by Bristol-Myers.
           ·4· ·Q.· · · Okay.                                                 ·4· · · · · ·This does not reference where the material
           ·5· · · · · ·Let's turn the page, and this is a -- it              ·5· ·was -- was shipped or whether it was used by any
           ·6· ·looks like a printout or invoice from E.S.                    ·6· ·particular company.
           ·7· ·Laboratories; right, a report?                                ·7· · · · · ·So, at this point it is just an analysis.
           ·8· ·A.· · · Yes.                                                  ·8· · · · · ·MS. KAGAN:· Right.
           ·9· ·Q.· · · And it says, "chemical analyses"; right?              ·9· · · · · · · · · · · · · - - -
           10· ·A.· · · Yes.                                                  10· ·CONTINUATION
           11· ·Q.· · · Customer, Whittaker, Clark and Daniels;               11· ·BY MS. KAGAN:
           12· ·right?                                                        12· ·Q.· · · And, again, my question to you is; was
           13· ·A.· · · Yes.                                                  13· ·Bristol-Myers aware of this positive finding of
           14· ·Q.· · · And then it has in the middle, Invoice                14· ·chrysotile asbestos in Italian talc in June of
           15· ·Number 1428; right?                                           15· ·1972?
           16· ·A.· · · Yes.                                                  16· · · · · ·MR. ULLOA:· Assumes facts not in evidence,
           17· ·Q.· · · And that is the same one that we saw on the           17· ·but that is what it is.
           18· ·first page; right, same invoice number?                       18· · · · · ·But you can answer, if you understand.
           19· ·A.· · · Yes.                                                  19· · · · · ·THE WITNESS:· Not to my knowledge.
           20· ·Q.· · · Okay.                                                 20· · · · · ·MS. KAGAN:· Okay.
           21· · · · · ·And then the last pages are curves; right?            21· · · · · ·We can put that aside.
           22· · · · · ·XROC curve.· If you recognize it to be that,          22· · · ·